2008
DOI: 10.3324/haematol.13285
|View full text |Cite
|
Sign up to set email alerts
|

Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma

Abstract: This phase I study compared pharmacokinetics and pharmacodynamics, and assessed safety and efficacy of intravenous and subcutaneous administration of bortezomib. Relapsed or refractory multiple myeloma patients were randomized to receive bortezomib by standard intravenous bolus (n=12) or subcutaneous injection (n=12) at the recommended dose and schedule (1.3 mg/m 2 , days 1, 4, 8, 11; eight 21-day cycles). Plasma bortezomib concentration and percent 20S proteasome inhibition were measured at multiple time poin… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

15
96
0

Year Published

2011
2011
2022
2022

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 109 publications
(111 citation statements)
references
References 11 publications
15
96
0
Order By: Relevance
“…Inhibition levels were also equivalent in patients with MM receiving 20 mg/m 2 carfilzomib as a 2‐ to 10‐min or 30‐min infusion, which is consistent with results reported in animals (Yang et al , 2011). It is noteworthy that the overall level of CT‐L inhibition seen with carfilzomib is higher than the 65–70% inhibition rate reported in bortezomib‐treated patients (Orlowski et al , 2002; Papandreou et al , 2004; Moreau et al , 2008). Using ProCISE, we also demonstrated that the administration of carfilzomib inhibits proteasome subunit occupancy in bone marrow–derived tumour cells.…”
Section: Discussionmentioning
confidence: 82%
“…Inhibition levels were also equivalent in patients with MM receiving 20 mg/m 2 carfilzomib as a 2‐ to 10‐min or 30‐min infusion, which is consistent with results reported in animals (Yang et al , 2011). It is noteworthy that the overall level of CT‐L inhibition seen with carfilzomib is higher than the 65–70% inhibition rate reported in bortezomib‐treated patients (Orlowski et al , 2002; Papandreou et al , 2004; Moreau et al , 2008). Using ProCISE, we also demonstrated that the administration of carfilzomib inhibits proteasome subunit occupancy in bone marrow–derived tumour cells.…”
Section: Discussionmentioning
confidence: 82%
“…Trials and retrospective analyses have shown that retreatment with bortezomib is feasible and effective and does not incur cumulative toxicity. [50][51][52] Lenalidomide retreatment is also feasible and may induce responses in up to 44 % of relapsed patients, and is better than retreatment with thalidomide. 51,53 Tolerability is another important consideration, and factors like neuropathy, myelosuppression and thrombosis may influence the choice of therapy.…”
Section: Retreatmentmentioning
confidence: 99%
“…Subsequently, we incubated whole blood for 1 hour with 100 nmol/L of bortezomib, a concentration/ exposure period maintained in patients receiving a dose of 1.3 mg/m 2 (19,27,28), and observed potent inhibition of CatG by ABP detection in isolated PBMCs. Carfilzomib, on the other hand, did not affect CatG activity despite equivalent levels of proteasome inhibition to bortezomib (Fig.…”
Section: Bortezomib Inhibits Serine Proteases In Intact Cells and In mentioning
confidence: 99%